V. De Angelis
University of Perugia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by V. De Angelis.
European Journal of Cancer | 2002
Mariantonietta Colozza; Giancarlo Bisagni; Anna Maria Mosconi; S. Gori; Corrado Boni; R. Sabbatini; Antonio Frassoldati; Rodolfo Passalacqua; A.Rosa Bian; Carmelina Rodinò; E. Rondini; R. Algeri; S. Di Sarra; V. De Angelis; Giorgio Cocconi; Maurizio Tonato
We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with <10 nodes were accrued. CMF was given intravenously (i.v.) on days 1 and 8, every 4 weeks, for six courses; epirubicin was given weekly for 4 months. Postmenopausal patients received tamoxifen for 3 years. The primary endpoints were overall survival (OS), relapse-free survival (RFS) and event-free survival (EFS). Outcome evaluation was performed both in eligible patients and in all randomised patients according to the intention-to-treat principle. 8 randomised patients were considered ineligible. At a median follow-up of 8 years, there was no difference in OS (Hazard Ratio (HR)=1.11, 95% Confidence Interval (CI): 0.77-1.61, P=0.58), EFS (HR=1.14, 95% CI: 0.78-1.64, P=0.48), and RFS (HR=1.14, 95% CI: 0.8-1.64, P=0.48) between the two arms for all of the patients. At 8 years, the RFS percentages (+/-Standard Error (S.E.)) were 65.4% (+/-4%) in the CMF arm and 62.7% (+/-4%) in the epirubicin arm; for EFS these were 64.2% (+/-4%) for CMF and 60.8% (+/-4%) for epirubicin, respectively. A significant difference in RFS (P=0.015) was observed in patients with 4-9 positive nodes in favour of the CMF arm. Toxicity in the two arms was superimposable except for more frequent grade 3 alopecia in the epirubicin-treated patients (P=0.001). Overall, at a median follow-up of 8 years, there were no differences between the two arms in terms of OS, EFS and RFS.
Journal of interferon research | 1994
Anna Marina Liberati; P. Garofani; V. De Angelis; F. Di Clemente; M.A. Horisberger; M. Cecchini; A.R. Betti; Lucia Palmisano; S. Astolfi; A. Nastari; A. Villa; S. Arzano
Journal of interferon research | 1994
Anna Marina Liberati; M.A. Horisberger; P. Garofani; V. De Angelis; A. Ferrajoli; F. Di Clemente; P. Caricchi; D. Adiuto; L. Fedeli; B. Palumbo
Haematologica | 1991
Anna Marina Liberati; Monica Schippa; M. G. Portuesi; M. G. Proietti; V. De Angelis; A. Ferrajoli; S. Cinieri; F. Di Clemente; Lucia Palmisano; P. Berruto
Haematologica | 1990
Anna Marina Liberati; S. Cinieri; Maria Senatore; M. G. Portuesi; V. De Angelis; F. Di Clemente; Monica Schippa; A. Ferrajoli; S. Arzano; P. Berruto
Interactive Cardiovascular and Thoracic Surgery | 2016
Valentina Tassi; Silvia Ceccarelli; Niccolò Daddi; Cristina Zannori; V. De Angelis; Lucio Cagini; Mark Ragusa; Francesco Puma
Ejso | 2015
Luigina Graziosi; Elisabetta Marino; V. De Angelis; Annibale Donini
Ejso | 2015
Luigina Graziosi; Elisabetta Marino; V. De Angelis; Annibale Donini
Interactive Cardiovascular and Thoracic Surgery | 2013
Niccolò Daddi; Marco Schiavon; P.L. Filosso; Giuseppe Cardillo; Marcello Carlo Ambrogi; A. De Palma; L. Luzzi; Alessandro Bandiera; Christian Casali; Alberto Ruffato; V. De Angelis
9th National Congress of Medical Oncology (AIOM) | 2007
Sergio Bracarda; Camillo Porta; C. Boni; Armando Santoro; Fabrizio Artioli; C. Di Bartolomeo; Antonio Contu; Donatello Gasparro; F. Di Costanzo; R. La Bianca; Alfredo Falcone; V. De Angelis; Claudia Caserta; L. Sordini